Arrowhead Pharma (ARWR) PT Lowered to $40 at RBC Capital

May 13, 2025 9:42 AM EDT Send to a Friend
RBC Capital analyst Luca Issi lowered the price target on Arrowhead Pharma (NASDAQ: ARWR) to $40.00 (from $42.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login